SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CCCC

C4 Therapeutics, Inc. (CCCC)

NASDAQ: CCCC · USD
Healthcare · Biotechnology
$2.48+$0.04 (+1.64%)
 
Market cap
$326M
Insider Score
Analyst consensus
Market Cap$325.67M+4.2%
Revenue (ttm)$32.28M
Net Income-$91.09M
EPS-$0.63
Shares Out131.32M
PE Ration/a
Forward PE-3.01
Dividendn/a
Ex-Dividend Daten/a
Volume3,628,833
Open$2.39
Previous Close$2.44
Day's Range$2.32 - $2.54
52-Week Range$1.69 - $5.17
Beta3.16
AnalystsStrong Buy
Price Target$12.50(+404.03%)
Earnings DateNov 5, 2026

About CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Address
490 Arsenal Way, Watertown, MA, 02472, United States
Market Cap
326 million
Employees
104
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$122.49K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $7.00 (+186.9%)

1 firm rating CCCC in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+1.64%
5 Days
-10.14%
1 Month
-22.01%
6 Months
-30.34%
1 Year
+4.20%

$CCCC stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CCCC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CCCC's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CCCC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CCCC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CCCC from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from CCCC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
1
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.44%
SBIOALPS Medical Breakthroughs ETF0.22%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.17%
IWCiShares Micro-Cap ETF0.07%
VFMOVanguard U.S. Momentum Factor ETF0.07%
FESMFidelity Enhanced Small Cap ETF0.04%
IBBQInvesco Nasdaq Biotechnology ETF0.02%
IBBiShares Biotechnology ETF0.02%
BIBProShares Ultra Nasdaq Biotechnology0.01%

Weight is the stock’s share of each fund’s holdings.